Teva Pharmaceutical Industries (NYSE:TEVA) Releases FY 2025 Earnings Guidance

Teva Pharmaceutical Industries (NYSE:TEVA) updated its FY 2025 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 2.550-2.650 for the period, compared to the consensus estimate of 2.530. The company issued revenue guidance of $16.8 billion-$17.0 billion, compared to the consensus revenue estimate of $16.9 billion.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on TEVA shares. JPMorgan Chase & Co. boosted their price objective on Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the company an “overweight” rating in a report on Friday, October 3rd. UBS Group boosted their price objective on Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the company a “buy” rating in a report on Wednesday, September 24th. Weiss Ratings restated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a report on Wednesday, October 8th. Finally, Wall Street Zen upgraded Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Saturday, October 11th. Two investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $25.57.

Teva Pharmaceutical Industries Trading Down 0.4%

Shares of NYSE:TEVA opened at $20.45 on Wednesday. The business’s 50-day moving average is $19.37 and its 200 day moving average is $17.66. Teva Pharmaceutical Industries has a 1 year low of $12.47 and a 1 year high of $22.80. The firm has a market capitalization of $23.45 billion, a P/E ratio of -127.79, a P/E/G ratio of 1.11 and a beta of 0.71. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.06 and a quick ratio of 0.77.

Institutional Trading of Teva Pharmaceutical Industries

A number of hedge funds have recently modified their holdings of TEVA. Peapack Gladstone Financial Corp acquired a new position in Teva Pharmaceutical Industries in the 2nd quarter worth about $174,000. Orion Porfolio Solutions LLC raised its holdings in shares of Teva Pharmaceutical Industries by 23.1% during the second quarter. Orion Porfolio Solutions LLC now owns 12,474 shares of the company’s stock valued at $209,000 after acquiring an additional 2,341 shares during the last quarter. Flow Traders U.S. LLC acquired a new stake in shares of Teva Pharmaceutical Industries in the second quarter valued at approximately $238,000. Franklin Resources Inc. acquired a new stake in shares of Teva Pharmaceutical Industries in the second quarter valued at approximately $255,000. Finally, State of Wyoming acquired a new stake in shares of Teva Pharmaceutical Industries in the second quarter valued at approximately $299,000. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.